{"title":"From pancreatic cancer to lung cancer, ZIP4’s oncogenic function continues","authors":"Shi-Yong Sun","doi":"10.21037/apc-22-2","DOIUrl":"https://doi.org/10.21037/apc-22-2","url":null,"abstract":"","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81369166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lawrence W. Wu, Syed M Qasim Hussaini, J. W. Lee, Daniel H Shu, R. Hruban, D. Laheru
{"title":"Transformation of metastatic nonfunctioning pancreatic neuroendocrine tumor into insulinoma—two case reports","authors":"Lawrence W. Wu, Syed M Qasim Hussaini, J. W. Lee, Daniel H Shu, R. Hruban, D. Laheru","doi":"10.21037/apc-22-1","DOIUrl":"https://doi.org/10.21037/apc-22-1","url":null,"abstract":"","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75545109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pancreatic neuroendocrine tumor in a 27-year-old patient with Cornelia de Lange syndrome: a case report","authors":"M. Wright, A. Kline, elliot k fishman, A. Javed","doi":"10.21037/apc-21-12","DOIUrl":"https://doi.org/10.21037/apc-21-12","url":null,"abstract":"","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79098482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"EBF2 contributes to pancreatic cancer progenitor cell differentiation and tumor suppression","authors":"H. Mathew, J. Barb, S. Bentzen, Sheelu Varghese","doi":"10.21037/apc-21-17","DOIUrl":"https://doi.org/10.21037/apc-21-17","url":null,"abstract":"","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85890671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Javed, S. Ronnekleiv-Kelly, A. Hasanain, M. Pflüger, J. Habib, M. Wright, Jin He, J. Cameron, elliot k fishman, S. Frank, M. Weiss, R. Burkhart
{"title":"Blood transfusion is associated with worse outcomes following pancreatic resection for pancreatic adenocarcinoma","authors":"A. Javed, S. Ronnekleiv-Kelly, A. Hasanain, M. Pflüger, J. Habib, M. Wright, Jin He, J. Cameron, elliot k fishman, S. Frank, M. Weiss, R. Burkhart","doi":"10.21037/apc-21-11","DOIUrl":"https://doi.org/10.21037/apc-21-11","url":null,"abstract":"","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83762461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Selected pre-operative factors which affect pancreaticoduodenectomy outcomes: a systematic review","authors":"T. Russell, P. Labib, S. Aroori","doi":"10.21037/apc-21-15","DOIUrl":"https://doi.org/10.21037/apc-21-15","url":null,"abstract":"","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75854576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01Epub Date: 2021-10-30DOI: 10.21037/apc-21-5
Matthew Williams, Umut Özbek, Jung-Yi Lin, Celina Ang
Background: To investigate racial disparities among unresectable/metastatic pancreatic ductal adenocarcinoma (PDA) patients treated with contemporary chemotherapy regimens at an urban center.
Methods: Retrospective review of all PDA patients treated at a single institution between 2012-2017. Continuous and categorical variables were tested using t-test, Mann-Whitney U, chi-squared or Fisher's exact test as appropriate. Kaplan-Meier curves were generated and Cox proportional hazards models were used to analyze survival outcomes.
Results: One hundred and forty-five patients identified as: White [69], African American (AA, 34), Asian [15], and Other [27]. Fifty-five-point-seven percent of patients received gemcitabine-based therapy vs. 36.6% received fluorouracil (5-FU) based therapy, specifically 26.1% received FOLFIRINOX and 43.7% received gemcitabine/nab-paclitaxel. In a univariable model, Asians had significantly worse overall survival (OS) than Whites [hazard ratio (HR) 2.74, P=0.013], but there were no OS differences between AA vs. Whites (HR 1.51, P=0.297) nor Other vs. Whites (HR 2.05, P=0.062). On multivariable analysis, Asians had worse OS compared to Whites (HR 2.62, P=0.018), and gemcitabine-based therapy was inferior to 5-FU-based therapy (HR 2.65, P=0.005). There were no OS differences between AA vs. Whites nor Other vs. Whites (HR 1.12, P=0.769 and HR 0.8, P=0.763, respectively).
Conclusions: In this series of advanced PDA patients treated with contemporary chemotherapy, AA and White patients had comparable outcomes, but Asians had worse OS than White patients.
{"title":"A single-institutional analysis of racial disparities in clinicopathologic characteristics, treatment selections, and outcomes in advanced-stage pancreatic cancer patients.","authors":"Matthew Williams, Umut Özbek, Jung-Yi Lin, Celina Ang","doi":"10.21037/apc-21-5","DOIUrl":"https://doi.org/10.21037/apc-21-5","url":null,"abstract":"<p><strong>Background: </strong>To investigate racial disparities among unresectable/metastatic pancreatic ductal adenocarcinoma (PDA) patients treated with contemporary chemotherapy regimens at an urban center.</p><p><strong>Methods: </strong>Retrospective review of all PDA patients treated at a single institution between 2012-2017. Continuous and categorical variables were tested using <i>t</i>-test, Mann-Whitney U, chi-squared or Fisher's exact test as appropriate. Kaplan-Meier curves were generated and Cox proportional hazards models were used to analyze survival outcomes.</p><p><strong>Results: </strong>One hundred and forty-five patients identified as: White [69], African American (AA, 34), Asian [15], and Other [27]. Fifty-five-point-seven percent of patients received gemcitabine-based therapy <i>vs.</i> 36.6% received fluorouracil (5-FU) based therapy, specifically 26.1% received FOLFIRINOX and 43.7% received gemcitabine/nab-paclitaxel. In a univariable model, Asians had significantly worse overall survival (OS) than Whites [hazard ratio (HR) 2.74, P=0.013], but there were no OS differences between AA <i>vs.</i> Whites (HR 1.51, P=0.297) nor Other <i>vs.</i> Whites (HR 2.05, P=0.062). On multivariable analysis, Asians had worse OS compared to Whites (HR 2.62, P=0.018), and gemcitabine-based therapy was inferior to 5-FU-based therapy (HR 2.65, P=0.005). There were no OS differences between AA <i>vs</i>. Whites nor Other <i>vs</i>. Whites (HR 1.12, P=0.769 and HR 0.8, P=0.763, respectively).</p><p><strong>Conclusions: </strong>In this series of advanced PDA patients treated with contemporary chemotherapy, AA and White patients had comparable outcomes, but Asians had worse OS than White patients.</p>","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5f/aa/nihms-1753997.PMC8711781.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39771786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01Epub Date: 2021-10-30DOI: 10.21037/apc-21-4
Muhammad A Rauf, Ioannis A Ziogas, Julia M Sealock, Lea K Davis, Manhal Izzy, Sophoclis P Alexopoulos, Lea K Matsuoka
Background: Malignancy is one of the known leading causes of death among long-term liver transplantation (LT) survivors. Pancreatic cancer has an incidence of 7.6/100,000 in North America and constitutes a diagnostic challenge post-LT.
Methods: This is a single-center, retrospective review of the electronic health records (EHRs) of LT recipients with pancreatic adenocarcinoma (1990-2019). The prevalence of pancreatic adenocarcinoma in our institutional non-LT population was assessed using an institutional de-identified database (Synthetic Derivative).
Results: Six out of 2,232 (0.27%) LT recipients were diagnosed with pancreatic adenocarcinoma. Median age at diagnosis was 66.0 years (IQR, 57.8-71.8 years). Median time from LT to pancreatic adenocarcinoma diagnosis was 8.9 years (IQR, 4.7-16.2 years), the median size on imaging was 3.2 cm (IQR, 3.1-4.7 cm), and all tumors were located on the head of the pancreas. Three patients underwent surgical resection (one with adjuvant chemotherapy), two underwent palliative care, and one palliative chemotherapy with gemcitabine and abraxane. Over a median follow-up of 220.5 days (IQR, 144.8-399.5 days), all six patients died due to disease progression (100%). Pancreatic adenocarcinoma was diagnosed in 5,033 out of 2,484,772 (0.20%) individuals in the Synthetic Derivative.
Conclusions: Our findings identified an increased incidence of pancreatic adenocarcinoma following LT compared to the general population.
背景:恶性肿瘤是已知的长期肝移植(LT)幸存者死亡的主要原因之一。胰腺癌在北美的发病率为7.6/10万，是肝移植后的诊断挑战。方法:这是一项单中心回顾性研究，对1990-2019年胰脏腺癌肝移植受者的电子健康记录(EHRs)进行了回顾。我们使用机构去识别数据库(合成衍生物)评估了机构非lt人群中胰腺腺癌的患病率。结果:2232例(0.27%)肝移植受者中有6例被诊断为胰腺腺癌。诊断时的中位年龄为66.0岁(IQR, 57.8-71.8岁)。从LT到胰腺腺癌诊断的中位时间为8.9年(IQR, 4.7-16.2年)，成像中位尺寸为3.2 cm (IQR, 3.1-4.7 cm)，所有肿瘤均位于胰腺头部。3例患者接受手术切除(1例辅助化疗)，2例接受姑息治疗，1例接受吉西他滨和abraxane姑息化疗。中位随访时间为220.5天(IQR, 144.8-399.5天)，6例患者均因疾病进展死亡(100%)。在合成衍生物中，2,484,772人中有5,033人(0.20%)被诊断为胰腺腺癌。结论:我们的研究结果表明，与普通人群相比，肝移植后胰腺腺癌的发病率增加。
{"title":"Pancreatic adenocarcinoma in liver transplant recipients: a case series.","authors":"Muhammad A Rauf, Ioannis A Ziogas, Julia M Sealock, Lea K Davis, Manhal Izzy, Sophoclis P Alexopoulos, Lea K Matsuoka","doi":"10.21037/apc-21-4","DOIUrl":"https://doi.org/10.21037/apc-21-4","url":null,"abstract":"<p><strong>Background: </strong>Malignancy is one of the known leading causes of death among long-term liver transplantation (LT) survivors. Pancreatic cancer has an incidence of 7.6/100,000 in North America and constitutes a diagnostic challenge post-LT.</p><p><strong>Methods: </strong>This is a single-center, retrospective review of the electronic health records (EHRs) of LT recipients with pancreatic adenocarcinoma (1990-2019). The prevalence of pancreatic adenocarcinoma in our institutional non-LT population was assessed using an institutional de-identified database (Synthetic Derivative).</p><p><strong>Results: </strong>Six out of 2,232 (0.27%) LT recipients were diagnosed with pancreatic adenocarcinoma. Median age at diagnosis was 66.0 years (IQR, 57.8-71.8 years). Median time from LT to pancreatic adenocarcinoma diagnosis was 8.9 years (IQR, 4.7-16.2 years), the median size on imaging was 3.2 cm (IQR, 3.1-4.7 cm), and all tumors were located on the head of the pancreas. Three patients underwent surgical resection (one with adjuvant chemotherapy), two underwent palliative care, and one palliative chemotherapy with gemcitabine and abraxane. Over a median follow-up of 220.5 days (IQR, 144.8-399.5 days), all six patients died due to disease progression (100%). Pancreatic adenocarcinoma was diagnosed in 5,033 out of 2,484,772 (0.20%) individuals in the Synthetic Derivative.</p><p><strong>Conclusions: </strong>Our findings identified an increased incidence of pancreatic adenocarcinoma following LT compared to the general population.</p>","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/80/af/nihms-1753613.PMC8612297.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39660956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Yonkus, J. Bergquist, R. Alva-Ruiz, T. Ivanics, E. Habermann, A. Abdelrahman, T. Grotz, S. Cleary, R. Smoot, D. Nagorney, M. Kendrick, T. Halfdanarson, M. Truty
Background: Pancreatic acinar cell carcinoma is a rare exocrine malignancy that is distinct from pancreatic ductal adenocarcinoma. We sought to describe its changing incidence, compare its natural history to that of pancreatic ductal adenocarcinoma, and evaluate impact of treatment modalities using the National Cancer Data Base, and Surveillance Epidemiology and End Results datasets. Methods: Patients with histologically confirmed diagnosis were identified from the National Cancer Data Base and Surveillance Epidemiology and End Results. Parametric univariate analyses were performed to compare patient characteristics, tumor types and outcomes. Incidence trends were calculated using Surveillance Epidemiology and End Results data and unadjusted Kaplan-Meier Survival analysis was performed using data from the National Cancer Data Base. Results: Incidence of acinar cell carcinoma significantly increased by 73% over the study period compared to only 22% for ductal adenocarcinoma (P<0.01). Unadjusted and adjusted stage-specific survival was substantially superior for acinar cell carcinoma versus ductal adenocarcinoma in all stages. Pancreatic acinar cell carcinoma demonstrated lower age at diagnosis, larger and lower grade tumors, was less likely to demonstrate histopathologic lymphovascular invasion, and more likely to undergo curative-intent resection with lower positive margins compared to ductal adenocarcinoma. Amongst resected patients, ductal carcinoma histology remained the strongest independent predictor of increased mortality hazard compared to pancreatic acinar cell carcinoma. Conclusions: Acinar cell carcinoma is a less aggressive malignancy with a significantly rising incidence of unknown etiology and better overall survival in both unadjusted analysis and after adjustment for clinically relevant predictors of mortality. 10 surgical resection. These findings, along with the improved overall survival at all stages, suggests that PACC is a less aggressive malignancy than PDAC. The 73% increase in incidence over a 12 year study period is of significant interest. The study demonstrated that the incidence is increasing at a much faster rate than PDAC. The reason for the increasing incidence is unknown and is a subject for further investigation which should be followed with interval studies. Possible explanations for this increased incidence is improvements in the ability to identify this histologic subtype, increased incidental identification during abdominal imaging for other purposes, or due to genetic factors.
{"title":"A national database analysis of acinar cell carcinoma of the pancreas, a histologically, epidemiologically, and biologically distinct entity increasing in incidence","authors":"J. Yonkus, J. Bergquist, R. Alva-Ruiz, T. Ivanics, E. Habermann, A. Abdelrahman, T. Grotz, S. Cleary, R. Smoot, D. Nagorney, M. Kendrick, T. Halfdanarson, M. Truty","doi":"10.21037/APC-21-1","DOIUrl":"https://doi.org/10.21037/APC-21-1","url":null,"abstract":"Background: Pancreatic acinar cell carcinoma is a rare exocrine malignancy that is distinct from pancreatic ductal adenocarcinoma. We sought to describe its changing incidence, compare its natural history to that of pancreatic ductal adenocarcinoma, and evaluate impact of treatment modalities using the National Cancer Data Base, and Surveillance Epidemiology and End Results datasets. Methods: Patients with histologically confirmed diagnosis were identified from the National Cancer Data Base and Surveillance Epidemiology and End Results. Parametric univariate analyses were performed to compare patient characteristics, tumor types and outcomes. Incidence trends were calculated using Surveillance Epidemiology and End Results data and unadjusted Kaplan-Meier Survival analysis was performed using data from the National Cancer Data Base. Results: Incidence of acinar cell carcinoma significantly increased by 73% over the study period compared to only 22% for ductal adenocarcinoma (P<0.01). Unadjusted and adjusted stage-specific survival was substantially superior for acinar cell carcinoma versus ductal adenocarcinoma in all stages. Pancreatic acinar cell carcinoma demonstrated lower age at diagnosis, larger and lower grade tumors, was less likely to demonstrate histopathologic lymphovascular invasion, and more likely to undergo curative-intent resection with lower positive margins compared to ductal adenocarcinoma. Amongst resected patients, ductal carcinoma histology remained the strongest independent predictor of increased mortality hazard compared to pancreatic acinar cell carcinoma. Conclusions: Acinar cell carcinoma is a less aggressive malignancy with a significantly rising incidence of unknown etiology and better overall survival in both unadjusted analysis and after adjustment for clinically relevant predictors of mortality. 10 surgical resection. These findings, along with the improved overall survival at all stages, suggests that PACC is a less aggressive malignancy than PDAC. The 73% increase in incidence over a 12 year study period is of significant interest. The study demonstrated that the incidence is increasing at a much faster rate than PDAC. The reason for the increasing incidence is unknown and is a subject for further investigation which should be followed with interval studies. Possible explanations for this increased incidence is improvements in the ability to identify this histologic subtype, increased incidental identification during abdominal imaging for other purposes, or due to genetic factors.","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89095110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Clark, N. Horick, Jill N. Allen, L. Blaszkowsky, Janet E. Murphy, C. Fuchs, B. Wolpin, R. Mayer, Jason E. Farris, J. Chan, K. Ng, N. McCleary, T. Abrams, D. Ryan, E. Kwak, T. Hong
Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital Cancer Center, Boston, MA, USA; Yale Cancer Center, New Haven, CT, USA; Dana Farber Cancer Institute, Boston, MA, USA; Dartmouth-Hitchcock Norris Cotton Cancer Center, One Medical Center Drive, Lebanon, NH, USA Contributions: (I) Conception and design: JW Clark, EL Kwak, TS Hong; (II) Administrative support: None; (III) Provision of study materials or patients: JW Clark, JN Allen, LS Blaszkowsky, JE Murphy, C Fuchs, BM Wolpin, RJ Mayer, JE Farris, JA Chan, K Ng, NJ McCleary, TA Abrams, DP Ryan, EL Kwak; (IV) Collection and assembly of data: JW Clark, N Horick, EL Kwak, TS Hong; (V) Data analysis and interpretation: JW Clark, N Horick, EL Kwak, TS Hong; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. These authors contributed equally to this work. Correspondence to: Jeffrey W. Clark, MD. Massachusetts General Hospital Cancer Center, 55 Fruit Street, 223 Bartlett Hall, Boston, MA 02114, USA. Email: clark.jeffrey@mgh.harvard.edu.
哈佛医学院，波士顿，马萨诸塞州，美国;美国马萨诸塞州波士顿总医院肿瘤中心;耶鲁大学癌症中心，美国康涅狄格州纽黑文;达纳法伯癌症研究所，波士顿，马萨诸塞州，美国;达特茅斯-希区柯克-诺里斯棉花癌症中心，黎巴嫩，新罕布什尔州，美国贡献:(一)概念和设计:JW Clark, EL Kwak, TS Hong;行政支助:无;(三)为患者提供研究资料:JW Clark, JN Allen, LS Blaszkowsky, JE Murphy, C Fuchs, BM Wolpin, RJ Mayer, JE Farris, JA Chan, K Ng, NJ McCleary, TA Abrams, DP Ryan, EL Kwak;(四)数据收集与组装:JW Clark, N Horick, EL Kwak, TS Hong;(五)数据分析与解释:JW Clark, N Horick, EL Kwak, TS Hong;(六)稿件撰写:全体作者;(七)稿件最终审定:全体作者。这些作者对这项工作贡献均等。收信人:Jeffrey W. Clark, MD. Massachusetts General Hospital Cancer Center，水果街55号，223 Bartlett Hall, Boston, MA 02114, USA。电子邮件:clark.jeffrey@mgh.harvard.edu。
{"title":"A Phase 1b clinical trial of LDE225 (Sonidegib) in combination with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) in previously untreated locally advanced or metastatic pancreatic adenocarcinoma","authors":"J. Clark, N. Horick, Jill N. Allen, L. Blaszkowsky, Janet E. Murphy, C. Fuchs, B. Wolpin, R. Mayer, Jason E. Farris, J. Chan, K. Ng, N. McCleary, T. Abrams, D. Ryan, E. Kwak, T. Hong","doi":"10.21037/APC-20-41","DOIUrl":"https://doi.org/10.21037/APC-20-41","url":null,"abstract":"Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital Cancer Center, Boston, MA, USA; Yale Cancer Center, New Haven, CT, USA; Dana Farber Cancer Institute, Boston, MA, USA; Dartmouth-Hitchcock Norris Cotton Cancer Center, One Medical Center Drive, Lebanon, NH, USA Contributions: (I) Conception and design: JW Clark, EL Kwak, TS Hong; (II) Administrative support: None; (III) Provision of study materials or patients: JW Clark, JN Allen, LS Blaszkowsky, JE Murphy, C Fuchs, BM Wolpin, RJ Mayer, JE Farris, JA Chan, K Ng, NJ McCleary, TA Abrams, DP Ryan, EL Kwak; (IV) Collection and assembly of data: JW Clark, N Horick, EL Kwak, TS Hong; (V) Data analysis and interpretation: JW Clark, N Horick, EL Kwak, TS Hong; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. These authors contributed equally to this work. Correspondence to: Jeffrey W. Clark, MD. Massachusetts General Hospital Cancer Center, 55 Fruit Street, 223 Bartlett Hall, Boston, MA 02114, USA. Email: clark.jeffrey@mgh.harvard.edu.","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73462285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号